✦ LIBER ✦

Hematopoietic stem cell gene therapy for adenosine deaminase deficient-SCID

✍ Scribed by Alessandro Aiuti; Immacolata Brigida; Francesca Ferrua; Barbara Cappelli; Robert Chiesa; Sarah Marktel; Maria-Grazia Roncarolo

Book ID: 107572438
Publisher: Springer-Verlag
Year: 2009
Tongue: English
Weight: 241 KB
Volume: 44
Category: Article
ISSN: 0257-277X
DOI: 10.1007/s12026-009-8107-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Development of selective amplifier genes

Development of selective amplifier genes for hematopoietic stem cell gene therapy

✍ Keiya Ozawa; Yutaka Hanazono; Akihiro Kume; Takeyuki Nagashima; Yasuji Veda; Kei 📂 Article 📅 2002 🏛 Carden Jennings Publishing 🌐 English ⚖ 216 KB

Selective Expansion of Transduced Cells

Selective Expansion of Transduced Cells for Hematopoietic Stem Cell Gene Therapy

✍ Akihiro Kume; Yutaka Hanazono; Hiroaki Mizukami; Takashi Okada; Keiya Ozawaa 📂 Article 📅 2002 🏛 Carden Jennings Publishing 🌐 English ⚖ 236 KB

Development of a modified selective ampl

Development of a modified selective amplifier gene for hematopoietic stem cell gene therapy

✍ Matsuda, K M; Kume, A; Ueda, Y; Urabe, M; Hasegawa, M; Ozawa, K 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 556 KB

Hematopoietic stem cell gene therapy for

Hematopoietic stem cell gene therapy for Niemann–Pick disease and other lysosomal storage diseases

✍ Edward H Schuchman 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 249 KB

Retroviral vector design studies toward

Retroviral vector design studies toward hematopoietic stem cell gene therapy for mucopolysaccharidosis type I

✍ Pan, D; Aronovich, E; McIvor, R S; Whitley, C B 📂 Article 📅 2000 🏛 Nature Publishing Group 🌐 English ⚖ 225 KB

PEG-ADA: An alternative to haploidentica

PEG-ADA: An alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency

✍ Michael S. Hershfield 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 596 KB

PEG-ADA is a long-circulating form of adenosine deaminase (ADA) that has been in use for > 8 years as replacement therapy for severe combined immunodeficiency disease due to ADA deficiency. Treatment with PEG-ADA almost completely corrects metabolic abnormalities, allowing the recovery of a variable